A review of Haemophilus influenzae disease in Europe from 2000-2014: challenges, successes and the contribution of hexavalent combination vaccines
- PMID: 28971707
- DOI: 10.1080/14760584.2017.1383157
A review of Haemophilus influenzae disease in Europe from 2000-2014: challenges, successes and the contribution of hexavalent combination vaccines
Abstract
The development of diphtheria-tetanus-acellular pertussis-Haemophilus influenzae type b (Hib) conjugate vaccine combinations culminated with hexavalent vaccines, the largest, most complex vaccine combinations in the immunization calendar. Hexavalent vaccines are used widely in Europe and are co-administered with multiple other recommended vaccines. Hib immunogenicity may reduce when combined with acellular pertussis antigens, or in some co-administrations. We reviewed the epidemiology of H. influenzae disease in Europe aiming to evaluate the current level of Hib control and indirectly assess the effectiveness against Hib of GSK's hexavalent vaccine in 10 countries where it is/has been used almost exclusively. Areas covered: We reviewed surveillance data from the European Union Invasive Bacterial Infections Surveillance Network and the European Surveillance System database from 1999-2014 and extracted case and incidence/notification rates (per 100,000 population) of invasive H. influenzae disease. We included age and serotype/strains distribution among countries in the European Union/European Economic Area region that reported to the European Centre for Disease Prevention and Control surveillance system. Expert commentary: The impact of Hib vaccination in Europe is sustained, testifying to continued effectiveness against invasive Hib disease after the implementation of hexavalent vaccines into immunization programs, which, since 2006, has been almost exclusively GSK´s hexavalent DTPa-HBV-IPV/Hib vaccine.
Keywords: Booster; Haemophilus influenzae; Hib disease; hexavalent vaccine; serotype; surveillance; vaccine.
Similar articles
-
Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.Hum Vaccin Immunother. 2017 Jul 3;13(7):1505-1515. doi: 10.1080/21645515.2017.1294294. Epub 2017 Mar 24. Hum Vaccin Immunother. 2017. PMID: 28340322 Free PMC article. Clinical Trial.
-
Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).Vaccine. 2017 Jun 27;35(30):3764-3772. doi: 10.1016/j.vaccine.2017.05.043. Epub 2017 Jun 2. Vaccine. 2017. PMID: 28583305 Clinical Trial.
-
Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.Hum Vaccin Immunother. 2014;10(10):2795-8. doi: 10.4161/21645515.2014.970494. Hum Vaccin Immunother. 2014. PMID: 25483640 Free PMC article.
-
Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).BioDrugs. 2010 Oct 1;24(5):299-302. doi: 10.2165/11206690-000000000-00000. BioDrugs. 2010. PMID: 20795752 Review.
-
Haemophilus influenzae type b conjugate vaccines - a South African perspective.Vaccine. 2012 Sep 7;30 Suppl 3:C52-7. doi: 10.1016/j.vaccine.2012.06.022. Vaccine. 2012. PMID: 22939022 Review.
Cited by
-
Effect of Haemophilus influenzae Type b Vaccination on Nasopharyngeal Carriage Rate in Children, Tehran, 2019.Biomed Res Int. 2021 Mar 15;2021:4923852. doi: 10.1155/2021/4923852. eCollection 2021. Biomed Res Int. 2021. PMID: 33816612 Free PMC article. Clinical Trial.
-
Importance of Virulence Factors for the Persistence of Oral Bacteria in the Inflamed Gingival Crevice and in the Pathogenesis of Periodontal Disease.J Clin Med. 2019 Aug 29;8(9):1339. doi: 10.3390/jcm8091339. J Clin Med. 2019. PMID: 31470579 Free PMC article. Review.
-
Molecular epidemiology of invasive Haemophilus influenzae disease in Portugal: an update of the post-vaccine period, 2011-2018.Eur J Clin Microbiol Infect Dis. 2020 Aug;39(8):1471-1480. doi: 10.1007/s10096-020-03865-0. Epub 2020 Mar 14. Eur J Clin Microbiol Infect Dis. 2020. PMID: 32172370
-
A Cross-Reactive Protein Vaccine Combined with PCV-13 Prevents Streptococcus pneumoniae- and Haemophilus influenzae-Mediated Acute Otitis Media.Infect Immun. 2019 Sep 19;87(10):e00253-19. doi: 10.1128/IAI.00253-19. Print 2019 Oct. Infect Immun. 2019. PMID: 31308088 Free PMC article.
-
Trends and health burden of hospitalized acute respiratory infections and impact of Haemophilus influenza immunization in a Tunisian university hospital: a twelve-year study.Libyan J Med. 2020 Dec;15(1):1783048. doi: 10.1080/19932820.2020.1783048. Libyan J Med. 2020. PMID: 32552441 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical